Agenus' bot/bal achieves 42% two-year survival in refractory mss crc, advances toward registration with fda alignment on phase 3

Lexington, mass.--(business wire)-- #cancercare--agenus inc. (nasdaq: agen) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (bot/bal) combination achieved a two-year survival rate of 42% along with a now more mature 21-month median overall survival (os) in an expanded cohort of 123 patients with microsatellite-stable (mss) metastatic colorectal cancer (mcrc) without active liver metastases (nlm). agenus also confirmed that it has reached agreement with the u.s. f.
AGEN Ratings Summary
AGEN Quant Ranking